Gaykema et al. performed a study to assess whether VEGF-A can be visualized by 89Zr-bevacizumab-PET in patients with primary breast cancer who were scheduled for surgery (Gaykema et al., 2013). The gene discussed is VEGFA; the disease is breast cancer.